The Haematology-Oncology Research Group (HORG) is the research arm of the National University Cancer Institute, Singapore (NCIS). HORG consists of haematologists and oncologists committed to the research of cancers endemic to Asia, with a special interest in the development of novel drugs for cancer treatment as well as improving existing treatments.
HORG strives to provide the best treatment options and care for patients through continuous research. In the area of pharmacogenetics, the research group is established as one of the global teams studying inter-ethnic variability in anti-cancer drugs. With a strong grounding in clinical pharmacology and molecular biology, combined with technology and clinical expertise, HORG is also involved in novel clinical trials especially in early-phase drug development.
HORG is also part of the Cancer Therapeutics Research Group (CTRG), now known as the Haematology-Oncology Research Group (HORG) was formed in 1997 under the leadership of Professor John Wong of NCIS and Professor James Bishop of the Sydney Cancer Centre with the aim of conducting clinical trials in the Asia-Pacific region.
Its objectives are: - To test new anticancer agents and strategies in Asian and Caucasian patients.
- To study the effect of anticancer agents in patients of different races.
- To develop better therapies for common cancers in the Asia-Pacific region.
- To provide high-quality data from recognised clinical trials for rapid approval of new anti-cancer compounds in Asia.
CTRG is a member of a large consortium of US-based institutions led by the Mayo Clinic that also conducts research in novel cancer drugs.
Such collaborations allow NCIS access to a large library of novel molecular agents made available from the US National Cancer Institute. Over the years, HORG has conducted clinical trials involving patients with cancers such as nasopharyngeal carcinoma, thyroid cancer, multiple myeloma, hepatocellular carcinoma, gastric cancer and breast cancer.
Today, CTRG works with nine partner institutions in the Asia-Pacific, which collectively bring extensive experience in oncology drug development. These partnerships have benefited patients in Singapore and the region, enabling them to have access to new anti-cancer treatments before they are available in the market.
Such clinical trials have advanced beyond traditional studies. CTRG has the expertise to measure molecular responses to novel drugs and understand how these drugs affect patients of various races differently, thus allowing better fine-tuning of the patients' treatments.
For more information, please contact:Haematology-Oncology Research Group (HORG)
c/o National University Cancer Institute, Singapore
1E Kent Ridge Road, NUHS Tower Block Level 7, Singapore 119228
Telephone: +65 6772 4619
Facsimile: +65 6872 3137 Email: horg@nuhs.edu.sg Website: http://www.horg.org.sg/
|
